Header Logo

Connection

YOCHAI BIRNBAUM to Animals

Back to Details
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Animals.
YOCHAI BIRNBAUM
Connection Strength
1.652
Animals
  1. Effects of Dapagliflozin on Myocardial Gene Expression in BTBR Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2025 Feb; 39(1):43-61.
    View in: PubMed
    Score: 0.050
  2. A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovasc Drugs Ther. 2024 Aug; 38(4):775-797.
    View in: PubMed
    Score: 0.046
  3. Recombinant Apyrase (AZD3366) Against Myocardial Reperfusion Injury. Cardiovasc Drugs Ther. 2023 08; 37(4):625-646.
    View in: PubMed
    Score: 0.045
  4. Do We Really Need Aspirin Loading for STEMI? Cardiovasc Drugs Ther. 2022 12; 36(6):1221-1238.
    View in: PubMed
    Score: 0.045
  5. Aspirin Blocks the Infarct-Size Limiting Effect of Ischemic Postconditioning in the Rat. Cardiovasc Drugs Ther. 2023 04; 37(2):221-224.
    View in: PubMed
    Score: 0.043
  6. Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era. Cardiovasc Drugs Ther. 2022 06; 36(3):525-532.
    View in: PubMed
    Score: 0.043
  7. Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus. Cardiovasc Drugs Ther. 2022 10; 36(5):829-840.
    View in: PubMed
    Score: 0.043
  8. Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. Cardiovasc Drugs Ther. 2019 10; 33(5):589-597.
    View in: PubMed
    Score: 0.038
  9. DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
    View in: PubMed
    Score: 0.038
  10. The Role of Non-coding RNAs in Ischemic Myocardial Reperfusion Injury. Cardiovasc Drugs Ther. 2019 08; 33(4):489-498.
    View in: PubMed
    Score: 0.038
  11. Ticagrelor Improves Remodeling, Reduces Apoptosis, Inflammation and Fibrosis and Increases the Number of Progenitor Stem Cells After Myocardial Infarction in a Rat Model of Ischemia Reperfusion. Cell Physiol Biochem. 2019; 53(6):961-981.
    View in: PubMed
    Score: 0.036
  12. Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction? J Cardiovasc Pharmacol Ther. 2019 05; 24(3):215-224.
    View in: PubMed
    Score: 0.036
  13. Size matters in STEMI: time for translation of ticagrelor? Cardiovasc Res. 2018 12 01; 114(14):1817-1818.
    View in: PubMed
    Score: 0.036
  14. Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovasc Drugs Ther. 2018 12; 32(6):553-558.
    View in: PubMed
    Score: 0.036
  15. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
    View in: PubMed
    Score: 0.034
  16. Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016 Dec; 30(6):539-550.
    View in: PubMed
    Score: 0.031
  17. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015 Aug; 35(8):1805-14.
    View in: PubMed
    Score: 0.028
  18. Statin-Induced Cardioprotection Against Ischemia-Reperfusion Injury: Potential Drug-Drug Interactions. Lesson to be Learnt by Translating Results from Animal Models to the Clinical Settings. Cardiovasc Drugs Ther. 2015; 29(5):461-7.
    View in: PubMed
    Score: 0.027
  19. PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. Cardiovasc Drugs Ther. 2014 Oct; 28(5):447-57.
    View in: PubMed
    Score: 0.027
  20. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014 Sep; 34(9):2078-85.
    View in: PubMed
    Score: 0.026
  21. Dipeptidyl peptidase IV inhibitors and ischemic myocardial injury. J Cardiovasc Pharmacol Ther. 2014 Sep; 19(5):417-25.
    View in: PubMed
    Score: 0.026
  22. Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on "Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a". Am J Physiol Cell Physiol. 2013 Mar; 304(6):C505-7.
    View in: PubMed
    Score: 0.024
  23. Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther. 2012 Dec; 26(6):445-56.
    View in: PubMed
    Score: 0.024
  24. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
    View in: PubMed
    Score: 0.024
  25. Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord. 2012 Dec; 10(6):387-90.
    View in: PubMed
    Score: 0.023
  26. Pleiotropic effects of statins: the role of eicosanoid production. Curr Atheroscler Rep. 2012 Apr; 14(2):135-9.
    View in: PubMed
    Score: 0.023
  27. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice. Cardiovasc Drugs Ther. 2011 Dec; 25(6):505-15.
    View in: PubMed
    Score: 0.022
  28. The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2011 Nov; 106(6):925-52.
    View in: PubMed
    Score: 0.022
  29. Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-?-independent manner. Basic Res Cardiol. 2011 May; 106(3):431-46.
    View in: PubMed
    Score: 0.021
  30. Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin. Cardiovasc Drugs Ther. 2010 Dec; 24(5-6):391-9.
    View in: PubMed
    Score: 0.021
  31. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 2011 May 01; 43(10):534-42.
    View in: PubMed
    Score: 0.020
  32. Resolvin E1 protects the rat heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H153-64.
    View in: PubMed
    Score: 0.020
  33. Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
    View in: PubMed
    Score: 0.020
  34. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010 May; 298(5):H1454-65.
    View in: PubMed
    Score: 0.020
  35. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol. 2008 Dec; 295(6):H2436-46.
    View in: PubMed
    Score: 0.018
  36. Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone. Cardiovasc Drugs Ther. 2008 Dec; 22(6):429-36.
    View in: PubMed
    Score: 0.018
  37. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol. 2008 Sep 01; 181(5):3515-23.
    View in: PubMed
    Score: 0.018
  38. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol. 2008 Jul; 295(1):H343-51.
    View in: PubMed
    Score: 0.017
  39. Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat. Cardiovasc Drugs Ther. 2008 Aug; 22(4):275-82.
    View in: PubMed
    Score: 0.017
  40. Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat. J Cardiovasc Pharmacol Ther. 2008 Mar; 13(1):72-9.
    View in: PubMed
    Score: 0.017
  41. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther. 2007 Oct; 21(5):321-30.
    View in: PubMed
    Score: 0.017
  42. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J. 2007 Aug; 154(2):391-402.
    View in: PubMed
    Score: 0.016
  43. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol. 2007 Sep; 293(3):H1918-28.
    View in: PubMed
    Score: 0.016
  44. Ultrasound at 27 kHz increases tissue expression and activity of nitric oxide synthases in acute limb ischemia in rabbits. Ultrasound Med Biol. 2007 Sep; 33(9):1483-8.
    View in: PubMed
    Score: 0.016
  45. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostaglandins Other Lipid Mediat. 2007 Aug; 84(1-2):43-53.
    View in: PubMed
    Score: 0.016
  46. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H813-8.
    View in: PubMed
    Score: 0.016
  47. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007 Jun; 292(6):H2891-7.
    View in: PubMed
    Score: 0.016
  48. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):89-98.
    View in: PubMed
    Score: 0.016
  49. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation. 2006 Aug 29; 114(9):929-35.
    View in: PubMed
    Score: 0.015
  50. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol. 2006 Sep; 291(3):H1158-69.
    View in: PubMed
    Score: 0.015
  51. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther. 2006 Feb; 20(1):27-36.
    View in: PubMed
    Score: 0.015
  52. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006 May; 290(5):H1960-8.
    View in: PubMed
    Score: 0.015
  53. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005 Feb 01; 65(2):345-55.
    View in: PubMed
    Score: 0.014
  54. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coron Artery Dis. 2004 Feb; 15(1):53-8.
    View in: PubMed
    Score: 0.013
  55. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther. 2003 Jan; 17(1):25-30.
    View in: PubMed
    Score: 0.012
  56. SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes. Cardiovasc Drugs Ther. 2022 12; 36(6):1091-1108.
    View in: PubMed
    Score: 0.011
  57. Noninvasive transthoracic low frequency ultrasound augments thrombolysis in a canine model of acute myocardial infarction--evaluation of the extent of ST-segment resolution. J Thromb Thrombolysis. 2001 May; 11(3):229-34.
    View in: PubMed
    Score: 0.011
  58. Augmentation of ultrasound-induced clot disruption by nongas-filled microparticles. Echocardiography. 2001 Apr; 18(3):265-8.
    View in: PubMed
    Score: 0.011
  59. Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
    View in: PubMed
    Score: 0.010
  60. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.
    View in: PubMed
    Score: 0.010
  61. Circulating blood cells and extracellular vesicles in acute cardioprotection. Cardiovasc Res. 2019 06 01; 115(7):1156-1166.
    View in: PubMed
    Score: 0.009
  62. Expression Profiling of Circular RNAs and Micrornas in Heart Tissue of Mice with Alcoholic Cardiomyopathy. Cell Physiol Biochem. 2018; 46(6):2284-2296.
    View in: PubMed
    Score: 0.009
  63. Noninvasive in vivo clot dissolution without a thrombolytic drug: recanalization of thrombosed iliofemoral arteries by transcutaneous ultrasound combined with intravenous infusion of microbubbles. Circulation. 1998 Jan 20; 97(2):130-4.
    View in: PubMed
    Score: 0.008
  64. Visualization of stents in the left anterior descending coronary artery by transthoracic echocardiography in pigs and humans. Am J Cardiol. 1998 Jan 15; 81(2):229-31.
    View in: PubMed
    Score: 0.008
  65. Unraveling the Interaction of Aspirin, Ticagrelor, and Rosuvastatin on the Progression of Atherosclerosis and Inflammation in Diabetic Mice. Cardiovasc Drugs Ther. 2017 Dec; 31(5-6):489-500.
    View in: PubMed
    Score: 0.008
  66. Regional remodeling of atherosclerotic arteries: a major determinant of clinical manifestations of disease. J Am Coll Cardiol. 1997 Nov 01; 30(5):1149-64.
    View in: PubMed
    Score: 0.008
  67. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation. 1997 Sep 02; 96(5):1641-6.
    View in: PubMed
    Score: 0.008
  68. The effect of CY1503, a sialyl Lewisx analog blocker of the selectin adhesion molecules, on infarct size and "no-reflow" in the rabbit model of acute myocardial infarction/reperfusion. J Mol Cell Cardiol. 1997 Aug; 29(8):2013-25.
    View in: PubMed
    Score: 0.008
  69. Changes in R wave amplitude: ECG differentiation between episodes of reocclusion and reperfusion associated with ST-segment elevation. J Electrocardiol. 1997 Jul; 30(3):211-6.
    View in: PubMed
    Score: 0.008
  70. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
    View in: PubMed
    Score: 0.008
  71. Differences in reperfusion length following 30 minutes of ischemia in the rabbit influence infarct size, as measured by triphenyltetrazolium chloride staining. J Mol Cell Cardiol. 1997 Feb; 29(2):657-66.
    View in: PubMed
    Score: 0.008
  72. Aleglitazar, a dual peroxisome proliferator-activated receptor-a and -? agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diab Vasc Dis Res. 2017 03; 14(2):152-162.
    View in: PubMed
    Score: 0.008
  73. The effect of coenzyme Q10 on infarct size in a rabbit model of ischemia/reperfusion. Cardiovasc Res. 1996 Nov; 32(5):861-8.
    View in: PubMed
    Score: 0.008
  74. Progressive decrease in the ST segment elevation during ischemic preconditioning: is it related to recruitment of collateral vessels? J Mol Cell Cardiol. 1996 Jul; 28(7):1493-9.
    View in: PubMed
    Score: 0.008
  75. Is preconditioning by nicotine responsible for the better prognosis in smokers with acute myocardial infarction? Basic Res Cardiol. 1996 May-Jun; 91(3):240-7.
    View in: PubMed
    Score: 0.007
  76. Aleglitazar, a Balanced Dual PPARa and -? Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovasc Drugs Ther. 2016 Apr; 30(2):129-41.
    View in: PubMed
    Score: 0.007
  77. Clinical aspects of myocardial stunning. Coron Artery Dis. 1995 Aug; 6(8):606-12.
    View in: PubMed
    Score: 0.007
  78. Therapy for myocardial stunning. Basic Res Cardiol. 1995 Jul-Aug; 90(4):291-3.
    View in: PubMed
    Score: 0.007
  79. Negative T wave in ischemic heart disease: a consensus article. Ann Noninvasive Electrocardiol. 2014 Sep; 19(5):426-41.
    View in: PubMed
    Score: 0.007
  80. Polymorphous ventricular tachycardia in the early stages of an evolving myocardial infarction. J Basic Clin Physiol Pharmacol. 1993 Oct-Dec; 4(4):347-56.
    View in: PubMed
    Score: 0.006
  81. MicroRNA-dependent cross-talk between VEGF and HIF1a in the diabetic retina. Cell Signal. 2013 Dec; 25(12):2840-7.
    View in: PubMed
    Score: 0.006
  82. Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN) crosstalk via microRNA interference in the diabetic heart. Basic Res Cardiol. 2013 May; 108(3):352.
    View in: PubMed
    Score: 0.006
  83. Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. Hypertension. 2013 May; 61(5):1008-13.
    View in: PubMed
    Score: 0.006
  84. Regulation of phosphatase and tensin homolog on chromosome 10 in response to hypoxia. Am J Physiol Heart Circ Physiol. 2012 May 01; 302(9):H1806-17.
    View in: PubMed
    Score: 0.006
  85. Reducing ischaemia/reperfusion injury through delta-opioid-regulated intrinsic cardiac adrenergic cells: adrenopeptidergic co-signalling. Cardiovasc Res. 2009 Dec 01; 84(3):452-60.
    View in: PubMed
    Score: 0.005
  86. Mediating delta-opioid-initiated heart protection via the beta2-adrenergic receptor: role of the intrinsic cardiac adrenergic cell. Am J Physiol Heart Circ Physiol. 2007 Jul; 293(1):H376-84.
    View in: PubMed
    Score: 0.004
  87. Systematic overview and clinical applications of pacing atrial stress echocardiography. Am J Cardiol. 2006 Aug 15; 98(4):549-56.
    View in: PubMed
    Score: 0.004
  88. A novel minimal-invasive model of chronic myocardial infarction in swine. Coron Artery Dis. 2004 Feb; 15(1):7-12.
    View in: PubMed
    Score: 0.003
  89. Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study. Thromb Res. 2003; 112(1-2):99-104.
    View in: PubMed
    Score: 0.003
  90. The use of transducer-tipped ultrasound catheter for recanalization of thrombotic arterial occlusions. Echocardiography. 2001 Apr; 18(3):233-7.
    View in: PubMed
    Score: 0.003
  91. Noninvasive transcutaneous low frequency ultrasound enhances thrombolysis in peripheral and coronary arteries. Echocardiography. 2001 Apr; 18(3):247-57.
    View in: PubMed
    Score: 0.003
  92. Noninvasive, transthoracic, low-frequency ultrasound augments thrombolysis in a canine model of acute myocardial infarction. Circulation. 2000 May 02; 101(17):2026-9.
    View in: PubMed
    Score: 0.002
  93. A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res. 1998 Jul; 39(1):216-23.
    View in: PubMed
    Score: 0.002
  94. Enhancement of thrombolysis in vivo without skin and soft tissue damage by transcutaneous ultrasound. Thromb Res. 1998 Feb 15; 89(4):171-7.
    View in: PubMed
    Score: 0.002
  95. beta-Estradiol, but not alpha-estradiol, reduced myocardial necrosis in rabbits after ischemia and reperfusion. Am Heart J. 1996 Aug; 132(2 Pt 1):258-62.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.